Table 2 Cytogenetic and fragile X testing in children with global developmental delay

ReferenceClassNResults*
* For references 7, 28, 29, and 41–45 (top of table), % of patients with abnormal results on cytogenetic studies; for references 48–56 (bottom of table), % of patients with fragile X (FraX).
Studies reporting cytogenetic and fragile X testing
    41III2,7572.93% (2.61% also had FraX)
    42III2563.9%
    43III2744.7% (9.1% also had FraX)
    44III1665.4%
    28III997.1%
    29III12011.6% (2.3% also had FraX)
    7IV6010%
    45IV1703.5%
Studies reporting data primarily on fragile X prevalence
    47II1,5810.7% FraX overall with 1.0% in males, 0.3% in females, and 7.6% in males with clinically pre-selected criteria
    48II800% females with FraX
    49II200% females with FraX
    50II2780.3% females with FraX
    51II1283.9% females with FraX
    52II504.0% females with FraX
    53II1944.1% females with FraX
    54II3511.4% females with FraX
    55III1033.9% FraX
    56IV4,9405.3% FraX